Waldencast PLC (NASDAQ:WALD) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts give Waldencast an average rating of "Hold" (1 sell, 1 hold, 3 buys) with a one-year consensus price target of $3.20, though several brokers recently cut targets to $2.00 and Weiss reiterated a sell.
• Institutional interest is rising: Stoic Point and Beartown bought new Q4 stakes (about $2.63M and $564k respectively) and institutions now own 41.97% of the stock.
• The stock trades near $0.99 with a 52-week range of $0.86–$3.22 and 50/200-day moving averages of $1.53/$1.81, while the company shows moderate liquidity (current ratio 1.70) and low leverage (debt/equity 0.29).

Shares of Waldencast PLC (NASDAQ:WALD - Get Free Report) have been given an average recommendation of "Hold" by the five analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $3.20.

Several brokerages have weighed in on WALD. Jefferies Financial Group began coverage on Waldencast in a report on Wednesday, January 14th. They issued a "buy" rating and a $2.00 price target for the company. Telsey Advisory Group cut their price target on Waldencast from $3.00 to $2.00 and set a "market perform" rating for the company in a report on Monday, March 16th. Canaccord Genuity Group cut their price target on Waldencast from $4.00 to $2.00 and set a "buy" rating for the company in a report on Monday, March 16th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Waldencast in a report on Wednesday, January 21st.

Institutional Trading of Waldencast

Several institutional investors have recently made changes to their positions in the stock. Beartown Capital Management LLC purchased a new stake in shares of Waldencast during the 4th quarter valued at $564,000. Stoic Point Capital Management LLC purchased a new stake in shares of Waldencast during the 4th quarter valued at $2,628,000. Barclays PLC grew its stake in shares of Waldencast by 11.0% during the 4th quarter. Barclays PLC now owns 66,337 shares of the company's stock valued at $125,000 after buying an additional 6,587 shares during the period. Wells Fargo & Company MN grew its stake in shares of Waldencast by 46.2% during the 4th quarter. Wells Fargo & Company MN now owns 47,484 shares of the company's stock valued at $89,000 after buying an additional 15,014 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Waldencast by 264.2% during the 4th quarter. Deutsche Bank AG now owns 43,205 shares of the company's stock valued at $81,000 after buying an additional 31,341 shares during the period. 41.97% of the stock is owned by hedge funds and other institutional investors.

Waldencast Price Performance

Shares of WALD opened at $0.99 on Tuesday. The stock has a fifty day moving average of $1.53 and a two-hundred day moving average of $1.81. The company has a current ratio of 1.70, a quick ratio of 0.97 and a debt-to-equity ratio of 0.29. Waldencast has a fifty-two week low of $0.86 and a fifty-two week high of $3.22.

About Waldencast

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.